Wells Fargo & Company Raises Revvity (NYSE:RVTY) Price Target to $110.00

Revvity (NYSE:RVTY) had its price target upped by analysts at Wells Fargo & Company from $107.00 to $110.00 in a report released on Tuesday,Benzinga reports. The brokerage currently has an “equal weight” rating on the stock. Wells Fargo & Company‘s price objective would suggest a potential upside of 2.82% from the stock’s previous close.

Other research analysts have also issued research reports about the company. Barclays increased their target price on Revvity from $115.00 to $118.00 and gave the stock an “overweight” rating in a research report on Tuesday. Robert W. Baird increased their price objective on Revvity from $122.00 to $123.00 and gave the stock an “outperform” rating in a report on Tuesday, October 28th. Weiss Ratings restated a “sell (d)” rating on shares of Revvity in a report on Monday, December 29th. Jefferies Financial Group upped their target price on shares of Revvity from $100.00 to $105.00 and gave the stock a “hold” rating in a research report on Monday. Finally, The Goldman Sachs Group began coverage on shares of Revvity in a research report on Tuesday, December 9th. They set a “neutral” rating and a $105.00 price target for the company. Five analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $110.82.

Revvity Stock Down 1.7%

Shares of NYSE RVTY opened at $106.98 on Tuesday. The firm has a fifty day simple moving average of $104.09 and a two-hundred day simple moving average of $95.52. Revvity has a 12 month low of $81.36 and a 12 month high of $126.57. The company has a current ratio of 1.75, a quick ratio of 1.44 and a debt-to-equity ratio of 0.36. The firm has a market capitalization of $12.13 billion, a PE ratio of 53.76, a price-to-earnings-growth ratio of 3.32 and a beta of 1.06.

Revvity (NYSE:RVTY) last announced its quarterly earnings results on Monday, February 2nd. The company reported $1.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.55 by $0.15. Revvity had a net margin of 8.44% and a return on equity of 7.52%. The company had revenue of $772.06 million for the quarter, compared to analysts’ expectations of $759.81 million. During the same quarter in the previous year, the company earned $1.42 earnings per share. Revvity’s quarterly revenue was up 5.9% on a year-over-year basis. Revvity has set its FY 2026 guidance at 5.350-5.450 EPS. Equities analysts expect that Revvity will post 4.94 earnings per share for the current year.

Revvity declared that its Board of Directors has approved a share buyback program on Monday, October 27th that permits the company to repurchase $1.00 billion in shares. This repurchase authorization permits the company to purchase up to 8.7% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company’s board believes its stock is undervalued.

Institutional Trading of Revvity

Several hedge funds and other institutional investors have recently made changes to their positions in the business. CYBER HORNET ETFs LLC acquired a new position in Revvity during the 2nd quarter valued at about $32,000. Cromwell Holdings LLC increased its holdings in shares of Revvity by 141.4% during the fourth quarter. Cromwell Holdings LLC now owns 338 shares of the company’s stock valued at $33,000 after acquiring an additional 198 shares in the last quarter. MUFG Securities EMEA plc purchased a new position in shares of Revvity in the 2nd quarter valued at approximately $34,000. CVA Family Office LLC boosted its stake in Revvity by 79.0% in the 2nd quarter. CVA Family Office LLC now owns 410 shares of the company’s stock worth $40,000 after purchasing an additional 181 shares in the last quarter. Finally, Headlands Technologies LLC purchased a new stake in Revvity during the 2nd quarter worth approximately $49,000. Hedge funds and other institutional investors own 86.65% of the company’s stock.

Key Revvity News

Here are the key news stories impacting Revvity this week:

• Positive Sentiment: Q4 results beat expectations — adjusted EPS $1.70 (vs. consensus ~ $1.55) and revenue $772.1M, up 5.9% year-over-year, showing improving top- and bottom-line momentum. Revvity Stock Up as Q4 Earnings Beat, Revenues In Line With Estimates
• Positive Sentiment: Company raised FY2026 guidance — EPS guidance of $5.35–$5.45 and ~ $3.0B revenue guidance that sit above Street estimates, signaling management confidence in diagnostics strength. Revvity forecasts 2026 profit, revenue above estimates after blowout fourth quarter
• Positive Sentiment: Immediate market reaction was positive as investors pushed the stock higher on the beat + outlook, supported by analyst notes highlighting the upside. Revvity, Inc. (RVTY) Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Management call/transcripts and slide deck are available — useful for investors wanting detail on segment trends, margin drivers and cadence of growth. Revvity (RVTY) Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Valuation debate: recent share weakness has prompted DCF/analyst pieces arguing the stock may be attractive vs. intrinsic value, but opinions vary — this may support longer-term buyers more than short-term traders. Is Revvity (RVTY) Attractive After Recent Share Price Weakness And DCF Valuation Gap
• Negative Sentiment: Headwinds remain in academic research funding, which could pressure parts of the business even as diagnostics performs well — a risk to sustaining growth across all segments. Revvity forecasts 2026 profit, revenue above estimates after blowout fourth quarter

About Revvity

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.